Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Clasificación en acciones #33642
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Precio por acción
$0.03702159
Última sincronización: 2024-01-29
Capitalización bursátil
$7.21M
Cambio (1 día)
-3.08%
Cambio (1 año)
0.00%
País
AU
Comercio Antisense Therapeutics Limited (ANP)

Categoría

EPS de Antisense Therapeutics Limited (ANP)
EPS a fecha de 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de Antisense Therapeutics Limited, el EPS actual de la empresa (TTM) es 0. Al final del año 2026, la empresa tenía un EPS de 0 igual a al EPS de 2026, que fue de 0.
Historial de EPS de Antisense Therapeutics Limited desde 2026 hasta 2026
EPS al final de cada año
Año EPS Cambiar
Not enough data for the provided dates.
EPS de empresas similares o competidoras